Novonix (NVX) Cash & Equivalents (2020 - 2025)

Novonix (NVX) has 6 years of Cash & Equivalents data on file, last reported at $79.9 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 87.48% year-over-year to $79.9 million; the trailing twelve-month figure through Dec 2025 stood at $79.9 million (up 87.48% YoY), and the FY2025 full-year result was $79.9 million, up 87.48% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $79.9 million, up from $42.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $148.3 million in Q2 2022 and bottomed at $42.6 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $89.5 million (2022), against an average of $92.3 million.
• The widest annual swing landed in 2021, when Cash & Equivalents surged 294.3%; it then sank 45.88% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $105.2 million in 2021, then fell by 5.89% to $99.0 million in 2022, then declined by 20.52% to $78.7 million in 2023, then sank by 45.88% to $42.6 million in 2024, then jumped by 87.48% to $79.9 million in 2025.
• The last three Cash & Equivalents figures came in at $79.9 million (Q4 2025), $42.6 million (Q4 2024), and $78.7 million (Q4 2023), per Business Quant data.

Peer Comparison